Kornimate/medical-research-clean huggingface dataset:
prevalence of hyponatremia in dengue infected patients: relationship with systemic inflammation.

Conditions: Hyponatremia; Dengue; Inflammation

Summary: prospective cohort study in patients with newly diagnosed dengue infection at hospital posadas in argentina, between january 1, 2016, and november 1, 2023. diagnosis was confirmed by igm serology or pcr. hyponatremia was defined as serum sodium concentration ≤135 meq/l.

background dengue infection is becoming more prevalent worldwide and is associated with systemic inflammation. systemic inflammation is associated with non-osmotic release of adh. methods: participants conducted a prospective cohort study in patients with newly diagnosed dengue infection at hospital posadas in argentina, between january 1, 2016, and november 1, 2023. diagnosis was confirmed by igm serology or pcr. hyponatremia was defined as serum sodium concentration ≤135 meq/l.

Eligibility criteria:
inclusion criteria: * diagnosis confirmed by pcr, non structural protein 1 (ns1) antigen or igm serology. plasma sodium at admission. exclusion criteria: * none

Keywords: hyponatremia dengue inflammation
abioscope ige assay to aid in the diagnosis of allergies

Conditions: Allergy; Allergic Asthma; Allergy to Cats; Allergy to House Dust; Allergy to Dog Dander; Allergy Cockroach

Summary: this is a multicenter, prospective, observational study designed to determine the clinical sensitivity and specificity of the abionic ivd capsule allergic asthma panel performed on abionic's abioscope device using k3-edta anticoagulated plasma samples from atopic and non-atopic pediatric and adult patients. patients' sensitization determined with the abioscope will be compared to the clinical assessment of allergy.


Eligibility criteria:
inclusion criteria: atopic and non-atopic individuals are needed for this study. for enrollment in the atopic arm, patients must meet all of the inclusion criteria listed below to be eligible for participation: 1. provide signed and dated written informed consent by patient or legally designated representative prior to any mandatory study-specific procedures, sample collection, or analysis. assent will be obtained from pediatric patients who are ≥ 6 years of age and less than 18 years of age. 2. male or female, ≥ 6 years of age. 3. consulting for signs and/or symptoms of ige-mediated allergies to perennial allergens. for enrollment in the non-atopic arm, patients must meet all of the inclusion criteria list below to be eligible for participation: 1. provide signed and dated written informed consent by patient or legally designated representative prior to any mandatory study-specific procedures, sample collection, or analysis. assent will be obtained from pediatric patients who are ≥ 6 years of age and less than 18 years of age. 2. male or female, ≥ 6 years of age. 3. apparently healthy individuals who exhibit no signs/symptoms of ige-mediated allergies including rhinitis, conjunctivitis, asthma, eczema, urticaria or food allergy symptoms upon exposure to animal danders, dust mites, cockroaches, pollens or food allergens (non-atopic). exclusion criteria: patients must not meet any exclusion criteria below to be eligible for participation: 1. patient participating in another study that may influence test results. 2. subjects taking any of the following medications: antihistamines in the week preceding the consultation, systemic steroids (inhaled or nasal steroids are allowed), anti-cytokines or cytokines, systemic interferon (injection local interferon α for the treatment of hpv is allowed), anti-ige therapy (approved or investigational) or treated with systemic chemotherapy. 3. on-going allergen immunotherapy or prior allergen immunotherapy within the prior 3 years. 4. patient with a history of cancer, autoimmune, or immune deficiency disease. 5. patient suffering from a hematological pathology (coagulation disorder, severe anemia) that could interfere with the blood test. 6. known severe allergic reaction to any of the ivd capsule allergic asthma panel allergen components

Keywords: allergy asthma point-of-care immunoassay in vitro diagnostic total ige specific allergy
functional mri use in prostate radiation treatment planning

Conditions: Prostate Cancer

Summary: this study is being done to evaluate the use of mri during radiation treatment planning to identify areas of tumor within the prostate to aid in future treatment planning and targeting of prostate cancer. this study will be conducted at the university of pennsylvania health system. the study is projected to run for 18 months. subjects will be male 18 or older with a prostate cancer diagnosis and treatment plansat the department of radiation oncology.


Eligibility criteria:
inclusion criteria: * age 18 or older * male * biopsy proven prostate cancer without evidence of metastatic disease * planned definitive external beam rt with daily erb and implanted visicoil fiducial markers. * prior fmri-ec documenting an ipl 25 mm2 in axial bidimensional diameter product, concordant with intraprostatic tumor location as documented on transrectal ultrasoundbiopsy * subject capable of giving informed consent for standard external beam rt and for the study. * no current contraindication that would prevent mri or gadolinium contrast. exclusion criteria: * metastatic disease * lack of fmri-ec documeneting an ipl 25 mm2 in axial bidimensional product, concordant with intraprostatic tumor location as documented on transrectal untrasound biopsy * neoadjuvant androgen deprivation therapy greater than 10 weeks, defined from date of lhrh analog injection to date of fmri-sim * contraindication that would prevent mri or gadolinium contrast * gfr 30 ml/min/1.73m2 per crockoft-gault formula.
function of inner ear such as balance and perception of verticality in children with idiopathic scoliosis

Conditions: Idiopathic Scoliosis; Vestibular Abnormality

Summary: the purpose of this study was to evaluate vestibular function in children with idiopathic scoliosis as a possible cause of etiopathogenesis of its diagnose.


Eligibility criteria:
inclusion criteria: * idiopathic scoliosis exclusion criteria: * operation of the spine * neurological disease * hearing problems

Keywords: idiopathic scoliosis subjective visual vertical vestibular evoked myogenic potentials posturography
study of bms-650032 with peginterferon alfa-2a plus ribavirin

Conditions: Hepatitis C Virus

Summary: the purpose of this study is to identify one or more doses of bms-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis c virus (genotypes 1 and 4).


Eligibility criteria:
inclusion criteria: * subjects chronically infected with hcv genotype 1 (phase 2a and phase 2b) * subjects chronically infected with hcv genotype 4 (phase 2b only) * hcv rna viral load of ≥ 10\*5\* iu/ml at screening * bmi of 18 - 35 kg/m² at screening exclusion criteria: * cirrhosis (phase 2a only) * decompensated cirrhosis (phase 2b) * co-infection with hbv or hiv * hepatocellular carcinoma * prior treatment with anti-hcv drugs
confocal endomicroscopy for biliary strictures -phase i

Conditions: Biliary Stricture

Summary: the investigators hypothesize that the confocal endomicroscopy imaging of the biliary strictures during ercp will differentiate between benign and malignant strictures in vivo and has increased sensitivity compared to biliary brushing/biopsy, and that direct cholangioscopic guidance of pcle is more accurate than fluoroscopic guidance.

despite recent advances in biliary imaging and biliary tissue acquisition, the diagnosis and tissue-confirmation in suspected malignant biliary obstruction remains challenging. patients often undergo repeat endoscopic and cross sectional imaging procedures, and even surgical exploration to establish a diagnosis. a major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pcle) system capable of cellular and sub-cellular imaging of the biliary tree. preliminary data suggests that pcle can accurately detect or exclude malignancy within otherwise indeterminate strictures. in this study, we propose to validate these preliminary findings and compare two methods of pcle image acquisition that are important for clinical translation of the technology. this is a phase 1 study: during this study, in vivo microscopic images of 10 benign (post-operative from know benign disease such as orthotopic liver transplant) and 10 malignant (cytology-positive) strictures will be obtained at ercp. patients clinical course will be followed and a composite gold standard will be used for comparison to pcle. these confocal images of biliary lesions will be reviewed side by side, unblinded to the reference standard by the endoscopists. the basic image characteristics allowing distinction between benign and malignant tissue will be established (details of features noted and examined are below). we will also assess whether good quality images can be feasibly obtained without the cholangioscopic guidance.

Eligibility criteria:
inclusion criteria: * pre-ercp: age above 18; imaging consistent with stenosis/mass of the hilum/extra-hepatic bile duct with abnormal liver chemistry, or painless jaundice referred for ercp. * evidence of biliary obstruction as defined by elevated direct bilirubin (\> 1.5uln) and dilation of the common or hepatic ducts \> 8mm) on imaging studies. exclusion criteria: * unwilling/unable to consent. * definite pancreatic mass on ct/mr. * allergy to fluorescein. * pregnancy (patient who could be pregnant will undergo pregnancy testing as per routine care) * indwelling metal biliary stent.

Keywords: biliary strictures cholangiocarcinoma ercp
early detection of glycocalyx damage in emergency room patients

Conditions: Sepsis; SIRS

Summary: aim of the study is to evaluate to what extent a glycocalyx damage measured in the er in patients presenting with sepsis correlates with their clinical course and if it can be used as a clinical stratification tool and mortality predictor. the study will focus on the changes of the microcirculation and how they correlate with the macrocirculation, as well as microbiologic parameters. in the study will participate ca. 300 patients with sepsis, as well as 30 patients without sepsis and 30 healthy individuals.


Eligibility criteria:
inclusion criteria: patients with suspected sepsis * adult patients presenting to the er with the clinical suspicion of infection * indication for hospital admission patients without sepsis * adult patients presenting to the er with other conditions apart from sepsis/infection. healthy individuals * adult healthy individuals. exclusion criteria (for all groups): * underage persons * pregnant women * oral mucosal injuries

Keywords: sepsis sirs glycocalyx glycocheck™-system infection
using visual arrays to support understanding of genetic risk

Conditions: Decision Aid

Summary: the goal of this study is to understand how people understand risk from genetic testing. the investigators want to understand what visual aid best helps people accurately assess risk. the investigators also want to understand how people relate risk to their health. the main questions the study aims to answer are: 1. which visual aid most accurately show genetic risk? 2. how do people perceive risk related to genetic test results? 3. what factors are associated with people discussing their results with family? participants will: 1. receive of of two visual aids showing risk 2. state their estimation of risk 3. answer questions about how they feel about risk and sharing information with family

this study aims to determine what visual aid helps people most accurately interpret risk from genetic test results. the study also examines how people perceive risk using the tripartite risk model. last, the study examines factors that are associated with intention to share genetic test results with family members. participants will provide brief sociodemographic information, complete brief health literacy and numeracy assessments, and questions about how they perceive risk. participants will be informed of a genetic testing scenario and will receive one of two visual aids. after reviewing the visual aid, participants will state the risk shown in the visual aid and will answer questions about their perceived risk and sharing results with family members (blood relatives).

Eligibility criteria:
inclusion criteria: * ability to read and understand english * opt-in consent exclusion criteria: * incorrect responses to validation questions

Keywords: lynch syndrome colorectal cancer colon cancer genetic testing
study of urinary kallikrein to enhance collateral circulation in symptomatic intracranial atherosclerosis

Conditions: Intracranial Arteriosclerosis; Collateral Circulation; Anterior Cerebral Circulation Infarction

Summary: the purpose of this study is to determine whether urinary kallikrein has an additional effect on enhancing collateral circulation in symptomatic intracranial atherosclerotic patients under clopidogrel and aspirin dual antiplatelet therapy.


Eligibility criteria:
inclusion criteria: 1. acute ischemic stroke or tia within 72 hours; 2. intracranial ica, mca m1 segment stenosis (\>70%) exclusion criteria: 1. \>70% stenosis in an intracranial artery other than the culprit artery. 2. \>50% stenosis of an extracranial carotid or vertebral artery on the ipsilateral side. 3. perforator strokes based on mri. 4. non-atherosclerotic lesion, for example, moyamoya disease, vascular inflammatory disease due to infection, autoimmunity diseases, developmental or genetic abnormalities, for example, fibromuscular dysplasia, sickle-cell anaemia, suspected vasospasm. 5. potential cardiac embolism as cause. 6. intracranial haemorrhage within 6 weeks. 7. concomitant intracranial tumour, aneurysm or arteriovenous malformation. 8. known contraindications for heparin, aspirin, clopidogrel or contrast. 9. haemoglobin \ 1.5, or other uncorrectable coagulopathies.impaired liver function (alanine aminotransferase or glutamic oxalacetic transaminase ≥ 3×upper limit of normal) or renal function (serum creatinie ≥ 1.5mg/dl); 10. a baseline modified rankin score of ≥3. 11. life expectancy of \<1 year due to the concomitant illness. 12. pregnant or lactating women. 13. long-term statins users. 14. history of mental instability or dementia.
effect of positive attitudes on behavior and wellness

Conditions: Burnout; Stress, Emotional

Summary: the covid-19 pandemic has undoubtedly elevated levels of stress to people all over the globe, but none more than to the providers on the front-line. the purpose of the study is to first, assess the effects of the pandemic on burnout, team cohesion, and resiliency among healthcare providers battling covid-19 together in a medical icu (micu). secondly, the investigators hope to then assess the effects of simple positive feedback on transforming culture and attitudes during times of major stress.


Eligibility criteria:
inclusion criteria: * front-line healthcare providers in the medical intensive care unit (micu): nurses, respiratory therapists, resident physicians, fellow physicians, and attending physicians exclusion criteria: * healthcare providers providing only consultatory care in the micu * front-line healthcare providers not working in the micu during the study period

Keywords: wellness healthcare burnout covid
a study in erectile dysfunction

Conditions: Erectile Dysfunction

Summary: the purpose of this trial is to evaluate if treatment with tadalafil once daily will allow men to return to normal erectile function in those who did not have normal erectile function following as-needed (prn) phosphodiesterase type 5 (pde5) inhibitor treatment.


Eligibility criteria:
inclusion criteria: * at least a 3-month history of erectile dysfunction (ed). * are able to read, understand and provide signed informed consent. * have an international index of erectile function-erectile function (iief-ef) domain score that is greater than or equal to 17 and less than 26 at screening. * have been taking a maximum dose of sildenafil citrate (100 milligram \[mg\]), vardenafil (20 mg), or tadalafil (20 mg) on as needed basis for at least one month prior to screening. * anticipate having the same female sexual partner during the study who is willing to participate in the required number of sexual intercourse attempts and complete study measures during the study. * agree to make at least four sexual intercourse attempts during both the 4-week as needed run-in period and the 4-week non-drug run-in period. * agree not to use any other erectile dysfunction (ed) treatment, including herbal therapy during the 4-week non-drug, run-in, the double-blind treatment period, the open label period and for 96 hours after the end of the study. partner inclusion criteria: * are female and at least 18 years of age at screening. * anticipate having the same male study subject as her sexual partner during the study. * able to read, understand and provide signed informed consent. * agree to make the required number of sexual intercourse attempts with the male sexual study partner during the study. * willing to participate in recording responses to the treatment satisfaction scale. exclusion criteria: * have an iief-ef domain score of greater than or equal to 26 at screening. * prior ineffective treatment with (or nonresponder to) any pde5 inhibitor * have previously used or are currently using any pde5 inhibitor once daily. * present with ed caused by other primary disorders or ed caused by untreated/inadequately treated endocrine disease. * partner unwilling to complete all study requirements. * history of radical prostatectomy or other pelvic surgery or penile implant, or a clinically significant penile deformity, in the opinion of the investigator * exhibit evidence of clinically significant renal insufficiency or hepatobiliary disease, or significant cardiac history as determined by the investigator * currently receive treatment with nitrates, cancer chemotherapy, or antiandrogens * have previously completed or withdrawn from this study or any other study investigating tadalafil for once-daily use.

Keywords: erectile dysfunction ed impotence
behavior change on oral cancer patients after a localized behavior change model intervention

Conditions: Oral Cancer

Summary: the purpose of this research is to apply this smoking cessation program on oral cancer patients, and to analyze the effectiveness of it.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of oral cancer * current smoker
real-time support for exercise persistence in copd

Conditions: Pulmonary Disease, Chronic Obstructive; COPD; Emphysema; Chronic Bronchitis

Summary: the purpose of this exploratory study is to determine the feasibility, acceptability, and efficacy of an exercise persistence intervention for patients with chronic obstructive pulmonary disease (copd) following pulmonary rehabilitation (pr).

exercise, a cornerstone of pr, is effective in improving dyspnea, functioning, and health related quality of life (hrql) in patients with copd. however, these improvements gradually dissipate following program completion. there are currently few successful interventions that support patients' persistence with community-based exercise after pr and that have closely monitored the potentially negative impact that copd exacerbations have on exercise behaviors. emerging technologies such as wirelessly enabled personal digital assistants (pda) may provide an innovative means to support exercise persistence through real-time collaborative monitoring of exercise and signs and symptoms of copd exacerbations and reinforcement to enhance exercise self-efficacy. patient graduates of two pr programs who have copd (n=20) will first undergo a 2-week run-in prior to being randomized to either the mobile (mobilizing support for long-term exercise) intervention or attention control for 6 months.

Eligibility criteria:
inclusion criteria: * moderate to severe copd (fev1/fvc \<70% and fev1%\<80%) * ability to speak, read and write english * age 40 or older * willingness to complete a 6 month program exclusion criteria: * illnesses such as bronchiectasis, active malignancies or other end stage diseases * plans to continue in a maintenance program after rehabilitation.

Keywords: exercise physical activity adherence
performance of the travoprost intraocular implant

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: to evaluate the performance of the travoprost intracameral implant by determining residual drug in explanted implants of the travoprost intracameral implant and by determining aqueous humor concentrations of travoprost free acid at specified timepoints post administration through 24 months


Eligibility criteria:
inclusion criteria: * diagnosis of either open angle glaucoma (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or ocular hypertenson * zero to three topical intraocular pressure lowering medications at the time of visit 1 (screening) exam. * best spectacle corrected visual acuity of 16 letters or more correctly read at 4 meters or better in each eye. * open angle as defined by shaffer grade ≥ 3 at slit-lamp at the planned implantation site exclusion criteria: * traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders * active ocular inflammation, infection or edema * clinically significant dystrophy (e.g., bullous keratopathy, fuch's dystrophy) or clinically significant guttata